Improving Sexual and Gender Minority Cancer Care: Patient and Caregiver Perspectives From a Multi-Methods Pilot Study.

bisexual and transgender cancer care delivery cancer health disparities gay lesbian multi-methods research sexual and gender minority cancer

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 10 12 2021
accepted: 08 04 2022
entrez: 23 5 2022
pubmed: 24 5 2022
medline: 24 5 2022
Statut: epublish

Résumé

Up to 1 million lesbian, gay, bisexual, and transgender (i.e., sexual and gender minority, SGM) individuals in the United States have histories of cancer. This medically underserved population is diverse, with complex sexualities and gender identities, and distinct health concerns. SGM persons experience disproportionate risks for, and rates of, anal, breast, cervical, colorectal, endometrial, lung, and prostate cancers, in addition to cancers affecting transgender persons who have undergone sex-reassignment. SGM individuals are linked by shared experiences of stigmatization as a minority population for which little cancer research has been conducted. SGM cancer patients frequently report reluctance to seek healthcare, have poorer outcomes following diagnosis, engage in elevated risk behaviors (i.e. smoking and alcohol use) even after cancer diagnosis, have difficulty making emotional adjustment to illness, and experience higher rates of psychological distress. They report less satisfaction with cancer care, deficiencies in patient-centeredness and shared decision-making, gaps in care, and social isolation. Minority stress resulting from experiences of anti-SGM sentiment and discrimination affects cancer patients and their informal cancer caregivers. Our paper presents findings from a pilot study to identify gaps and opportunities to improve cancer care for SGM patients and caregivers at the University of New Mexico Comprehensive Cancer Center. Between June 2020 and July 2021, we used a multi-methods research design informed by ecological theory to collect qualitative and quantitative data regarding cancer patient and caregiver quality of life (QoL) and experiences of cancer and survivorship care. We used PROMIS measures distributed Results of the PROMIS QoL assessments indicated that SGM patients reported greater anxiety [mean (SD) = 54.5 (8.8)] and depression [mean (SD) = 49.3 (4.8)] than H/C patients [mean (SD)=51.6 (7.5) and 45.4 (6.8) respectively], while heterosexual, cisgender (H/C) patients reported higher fatigue [mean (SD) =52.04 (8.18)] and stronger pain intensity than SGM patients [mean (SD)=48.3 (9.1) and 37.8 (9.1) respectively]. SGM patients reported higher levels of social isolation [mean (SD) = 48.3 (7.3) vs. 42.1 (7.4) for H/C patients, whereas H/C patients reported more emotional support (mean (SD) =57.5 (9.3) vs. 53.0 (6.9)] and companionship [mean (SD) = 55.2 (8.6) vs. 51.5 (11.0)]. SGM and H/C differences in caregiver QoL were most notable with regards to higher levels of fatigue [mean (SD) = 47.1 (6.0) for SGM, and 42.4 (11.5) for H/C] and companionship [mean (SD) = 55.3 (6.0) for SGM, and 50.9 (5.5) for H/C]. Qualitative interviews supported our quantitative results. SGM patients and caregivers articulated experiences of anti-SGM stigma and discrimination contributing to minority stress that influenced their initial cancer care encounters. SGM dyads had more trepidation and/or medical mistrust during initial cancer care encounters when compared to H/C patients and caregivers. SGM patients questioned care that was not culturally responsive to SGM preferences, while H/C patients were more apt to identify gaps in communication and perceived lack of clarity regarding cancer care delivery. Although SGM patients experienced high satisfaction with their cancer care once they developed trust with their providers, they discussed desires to have more direct conversations with their oncologists about their sexual orientation and gender identities and sexual health. All patients and providers in the study (SGM and H/C) appreciated their oncology care teams. All patients and caregivers relied on social networks comprised of friends and family, although SGM patients and caregivers had smaller social networks and relied less on biological family, and single SGM individuals experienced challenges accessing cancer care and struggled with social isolation. We discovered too, that all caregivers, regardless of Sexual Orientation and Gender Identity (SOGI), perceived a lack of support and information pertaining to their loved one's treatment, side effects and best way to provide care. This study demonstrates that prior stigmatizing experiences contribute to minority stress and medical mistrust for SGM cancer patients and their informal caregivers across the cancer care experience. Findings point to specific gaps in SGM cancer patient care, including lack of conversation about patient SOGI, inadequate staff and oncology provider SGM specific knowledge and cultural competence/cultural humility training, and insufficient patient supports for those who lack social support during cancer care treatment. Further, this study reveals inadequacies in SGM specific support, and overall support services for informal cancer caregivers. Additional research is required to develop targeted interventions to address minority stress and clinic environment concerns to improve cancer care for SGM patients. Importantly, while there were differences between SGM and H/C experiences of cancer treatment, significant similarities also emerged. Caregiver expressed consensus about the current lack of support and guidance for informal caregivers of cancer patients. Future work should focus on providing caregiver-specific resources in the clinic setting and facilitating support groups for caregivers to network with one another, as well as for tailoring SGM specific caregiver support services. Our findings highlight areas for improving cancer care for the SGM community, as well as a broader population of patients and caregivers.

Identifiants

pubmed: 35600396
doi: 10.3389/fonc.2022.833195
pmc: PMC9120769
doi:

Types de publication

Journal Article

Langues

eng

Pagination

833195

Informations de copyright

Copyright © 2022 Kano, Jaffe, Rieder, Kosich, Guest, Burgess, Hurwitz, Pankratz, Rutledge, Dayao and Myaskovsky.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Oncol. 2013 May 1;31(13):1683-9
pubmed: 23530105
J Psychosoc Oncol. 2016;34(1-2):28-38
pubmed: 26577277
Health Psychol. 2017 Jun;36(6):529-537
pubmed: 28165265
J Health Soc Behav. 2021 Sep;62(3):318-333
pubmed: 34528481
LGBT Health. 2014 Jun;1(2):86-92
pubmed: 26789618
Qual Life Res. 2012 Mar;21(2):225-36
pubmed: 21660650
Psychooncology. 2018 Oct;27(10):2389-2397
pubmed: 29959808
Psychooncology. 2015 Nov;24(11):1384-91
pubmed: 25630987
Am J Public Health. 2013 Oct;103(10):1802-9
pubmed: 23763391
Obesity (Silver Spring). 2007 Apr;15(4):1023-8
pubmed: 17426338
Int J Environ Res Public Health. 2021 Feb 10;18(4):
pubmed: 33578997
Semin Oncol Nurs. 2018 Feb;34(1):3-11
pubmed: 29284587
J Homosex. 2014;61(6):889-98
pubmed: 24392702
LGBT Health. 2021 Jan;8(1):68-78
pubmed: 33325783
Annu Rev Public Health. 2006;27:297-322
pubmed: 16533119
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Consult Clin Psychol. 2012 Jun;80(3):382-95
pubmed: 22409643
Oncol Nurs Forum. 2009 Mar;36(2):203-7
pubmed: 19273409
CA Cancer J Clin. 2015 Sep-Oct;65(5):384-400
pubmed: 26186412
Am J Public Health. 2010 Oct;100(10):1953-60
pubmed: 20516373
Psychol Bull. 2003 Sep;129(5):674-697
pubmed: 12956539
Semin Oncol Nurs. 2018 Feb;34(1):52-59
pubmed: 29275016
Psychiatr Serv. 2006 Jun;57(6):867-70
pubmed: 16754766
Assessment. 2004 Sep;11(3):216-23
pubmed: 15358877
J Clin Epidemiol. 2016 May;73:119-27
pubmed: 26931289
Semin Oncol Nurs. 2018 Feb;34(1):72-79
pubmed: 29284588
J Cancer Educ. 2020 Feb;35(1):44-53
pubmed: 30377952
J Clin Epidemiol. 2016 Jun;74:194-206
pubmed: 26628334
Psychooncology. 2018 Jun;27(6):1480-1489
pubmed: 29462496
Arch Sex Behav. 2017 Oct;46(7):2043-2057
pubmed: 27102603
Semin Oncol Nurs. 2018 Feb;34(1):30-36
pubmed: 29325815
LGBT Health. 2015 Dec 24;3(1):1-2
pubmed: 26698385
Health Psychol. 2005 May;24(3):288-96
pubmed: 15898865
Psychiatr Serv. 2006 Jun;57(6):871-4
pubmed: 16754767
Oncol Nurs Forum. 2015 Jan;42(1):44-51
pubmed: 25542320
J Consult Clin Psychol. 2003 Feb;71(1):53-61
pubmed: 12602425
Semin Oncol Nurs. 2018 Feb;34(1):21-29
pubmed: 29338894
Soc Sci Med. 2008 Aug;67(3):368-79
pubmed: 18433961
Support Care Cancer. 2018 Apr;26(4):1189-1196
pubmed: 29080921
Med Care. 2008 Sep;46(9 Suppl 1):S62-7
pubmed: 18725835
Radiography (Lond). 2021 May;27(2):633-644
pubmed: 32800429
J Clin Oncol. 2019 Mar 1;37(7):547-558
pubmed: 30650044
LGBT Health. 2019 Aug/Sep;6(6):271-288
pubmed: 31314662
J Natl Cancer Inst Monogr. 2012 May;2012(44):2-10
pubmed: 22623590

Auteurs

Miria Kano (M)

Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, United States.
University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

Shoshana Adler Jaffe (SA)

University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

Stephanie Rieder (S)

University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.
Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM, United States.

Mikaela Kosich (M)

University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

Dolores D Guest (DD)

Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, United States.
University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

Ellen Burgess (E)

University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

Ariel Hurwitz (A)

University of New Mexico School of Medicine, Albuquerque, NM, United States.

Vernon Shane Pankratz (VS)

Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, United States.
University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

Teresa L Rutledge (TL)

University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.
Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM, United States.

Zoneddy Dayao (Z)

Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, United States.
University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

Larissa Myaskovsky (L)

Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, United States.
University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.
Center for Healthcare Equity in Kidney Disease (CHEK-D), University of New Mexico Health Sciences Center, Albuquerque, NM, United States.

Classifications MeSH